🇺🇸 IL-2 (interleukin 2) in United States
11 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 11
Most-reported reactions
- Rash — 2 reports (18.18%)
- Bradycardia — 1 report (9.09%)
- Coronary Artery Disease — 1 report (9.09%)
- Deep Vein Thrombosis — 1 report (9.09%)
- Fatigue — 1 report (9.09%)
- Hypertension — 1 report (9.09%)
- Hypoaesthesia — 1 report (9.09%)
- Libido Decreased — 1 report (9.09%)
- Musculoskeletal Stiffness — 1 report (9.09%)
- Nausea — 1 report (9.09%)
Other Oncology, Immunology approved in United States
Frequently asked questions
Is IL-2 (interleukin 2) approved in United States?
IL-2 (interleukin 2) does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for IL-2 (interleukin 2) in United States?
King's College London is the originator. The local marketing authorisation holder may differ — check the official source linked above.